GHD Clinical Trial
Official title:
The Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency: An Open-label, Single-arm, Multicenter Phase 3 Study
The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive.
The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00553852 -
Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity
|
Phase 3 | |
| Not yet recruiting |
NCT06007417 -
A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency
|
Phase 3 |